Details for Patent: 10,519,146
✉ Email this page to a colleague
Which drugs does patent 10,519,146 protect, and when does it expire?
Patent 10,519,146 protects LUMAKRAS and is included in one NDA.
This patent has seventy-six patent family members in thirty-eight countries.
Summary for Patent: 10,519,146
| Title: | KRAS G12C inhibitors and methods of using the same |
| Abstract: | Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers. |
| Inventor(s): | Brian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, David John KOPECKY, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Nobuko Nishimura, Youngsook Shin, Nuria A. Tamayo, John Gordon Allen, Jennifer Rebecca Allen |
| Assignee: | Amgen Inc |
| Application Number: | US15/984,855 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; |
| Patent landscape, scope, and claims: |
More… ↓ |
Recent additions to Drugs Protected by US Patent 10,519,146
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc | LUMAKRAS | sotorasib | TABLET | 214665 | May 28, 2021 | RX | Yes | 10,519,146 | Y | Y | ⤷ Start Trial | |||
| Amgen Inc | LUMAKRAS | sotorasib | TABLET | 214665 | Jun 26, 2024 | RX | Yes | 10,519,146 | Y | Y | ⤷ Start Trial | |||
| Amgen Inc | LUMAKRAS | sotorasib | TABLET | 214665 | Jan 20, 2023 | RX | Yes | 10,519,146 | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 10,519,146
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc | LUMAKRAS | sotorasib | TABLET;ORAL | 214665-001 | May 28, 2021 | RX | Yes | No | 10,519,146 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Amgen Inc | LUMAKRAS | sotorasib | TABLET;ORAL | 214665-003 | Jun 26, 2024 | RX | Yes | No | 10,519,146 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Amgen Inc | LUMAKRAS | sotorasib | TABLET;ORAL | 214665-002 | Jan 20, 2023 | RX | Yes | Yes | 10,519,146 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,519,146
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 111882 | ⤷ Start Trial | |||
| Argentina | 122783 | ⤷ Start Trial | |||
| Argentina | 122784 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
